Thyrocare Technologies’ Net Profit Up by 62% in June Quarter

Mumbai, July 23, 2025 –  Thyrocare Technologies Ltd (NSE: THYROCARE, BSE: 539871) reported consolidated revenue of ₹193 crore, a 23% YoY rise, with EBITDA increasing 35.5% to ₹57.8 crore, resulting in an EBITDA margin of 29.9%. Net profit increased 62% YoY to ₹38.9 crore, driven by strong demand for its diagnostic services.

As of July 23, the stock closed the day at ₹1,200.00, up by ₹12.50 or 1.05%.

For Q1FY26, the company reported strong standalone and consolidated financial performance with significant year-on-year and quarter-on-quarter growth. On a standalone basis – revenue from operations rose to ₹178.89 crore, marking a 24.6% YoY and 2.9% QoQ increase. EBITDA stood at approximately ₹52.13 crore, up 22.6% YoY and 7.7% QoQ. Net profit surged to ₹36.05 crore, reflecting a sharp 43.3% YoY and 64.2% QoQ growth, while basic EPS improved to ₹6.78 from ₹4.75 in Q1FY25 and ₹4.07 in Q4FY25. The company’s CFO resigned effective today. The company has appointed Vikram Gupta as the new CFO.

On a consolidated basis, revenue from operations came in at ₹193.03 crore, up 23.1% YoY and 3.1% QoQ. Net profit jumped 59.9% YoY and 77.5% QoQ to ₹38.29 crore, while basic EPS increased to ₹7.35 from ₹4.52 in Q1FY25 and ₹4.17 in Q4FY25. Segment-wise, Diagnostic Services contributed ₹178.33 crore with a 24.5% YoY growth, Imaging Services brought in ₹14.04 crore with 7.7% YoY growth, and the ‘Others’ segment remained flat at ₹0.66 crore.

Corporate Announcements

1. CFO Transition

• Outgoing CFO: Mr. Alok Kumar Jagnani resigned as Chief Financial Officer effective July 23, 2025.
• Incoming CFO: Mr. Vikram Gupta, a Chartered Accountant with over 20 years of experience (formerly at Rebel Foods, Tata Play Fiber, and Vodafone Idea), has been appointed as CFO and KMP, effective July 24, 2025.

2. Board Reshuffle

• Mr. Alok Kumar Jagnani has been appointed as a Non-Executive, Non-Independent Director, effective July 24, 2025, subject to shareholder approval.
• Mr. Hardik Kishor Dedhia, Non-Executive, Non-Independent Director, resigned from the Board and associated committees, citing personal commitments.

3. Senior Management Changes

• Mr. Amit Bhola, Vice President – Franchisee Operations, resigned effective July 31, 2025.
• Mr. Piyush Singh, previously VP – Partnership Operations, will take over the Franchisee Operations role, continuing as a Senior Managerial Personnel.

Other Key Developments

• Code of Conduct Update: The board approved an amendment to the Insider Trading Code under SEBI (PIT) Regulations, 2015.
• Tanzania Subsidiary Update: Thyrocare Laboratories (Tanzania) became a subsidiary (holding increased to 57.25%) effective April 1, 2025. An additional ₹1.50 Cr investment was made via CCPS during the quarter.

Management Commentary

Rahul Guha, Managing Director & CEO, stated:

“We’ve delivered strong operational performance across diagnostic and imaging verticals with robust margin improvements. The leadership changes further strengthen our strategic capability as we scale diagnostics with a digital-first approach across geographies.”

About Thyrocare Technologies Ltd

Thyrocare Technologies Ltd is a BSE and NSE-listed diagnostic company headquartered in Navi Mumbai, specializing in preventive and wellness testing. It operates pan-India and has international presence via its subsidiaries. As of Q1FY26, it holds a consolidated asset base of ₹737.60 crore and net worth of ₹592.69 crore.

REF:https://www.bseindia.com/xml-data/corpfiling/AttachLive/996b63e4-7742-4b9c-a419-0f6347440ac9.pdf

Disclaimer:  At HDFC SKY, we take utmost care and due diligence in curating and presenting news and market-related content. However, inadvertent errors or omissions may occasionally occur.

If you have any concerns, questions, or wish to point out any discrepancies in our content, please feel free to write to us at content@hdfcsec.com.

Please note that the information shared is intended solely for informational purposes and does not make any investment recommendations